Researchers at Mayo Clinic have unveiled a novel function of TRAILshort, a protein that inhibits T-cell activity, thereby diminishing immune responses to cancer and infections. The findings, published in the Journal of Clinical Investigation, reveal heightened levels of TRAILshort in various cancers including melanoma, lung, breast, pancreatic, and ovarian as well as Hodgkin lymphoma. In preclinical studies, the inhibition of TRAILshort led to the restoration of T-cell activity and enhanced responses to CAR-T therapy. The team suggests that this protein could eventually serve as a target for therapies related to cancer and immune disorders, although additional research is required to assess its safety and efficacy in patients.
Disclosure:This video contains stock footage and content created or enhanced using Ai-assisted tools ai-generated
